CEN Biotech, Inc.
CENBF
$0.0001
$0.000.00%
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 135.90K | 542.50K | 340.30K | 354.70K | 272.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 135.90K | 542.50K | 340.30K | 354.70K | 272.20K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 135.90K | 542.50K | 340.30K | 354.70K | 272.20K |
| SG&A Expenses | 622.20K | 842.50K | 480.10K | 727.00K | 917.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 622.20K | 842.50K | 480.10K | 727.00K | 917.10K |
| Operating Income | -486.40K | -300.00K | -139.90K | -372.30K | -645.00K |
| Income Before Tax | -400.20K | -348.30K | -258.90K | -2.10M | -718.90K |
| Income Tax Expenses | -- | -- | -- | -36.40K | -- |
| Earnings from Continuing Operations | -400.20K | -348.30K | -258.90K | -2.07M | -718.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -400.20K | -348.30K | -258.90K | -2.07M | -718.90K |
| EBIT | -486.40K | -300.00K | -139.90K | -372.30K | -645.00K |
| EBITDA | -285.50K | -274.80K | -46.00K | -264.60K | -503.50K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.04 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.04 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 63.99M | 61.34M | 42.42M | 53.79M | 47.34M |
| Average Diluted Shares Outstanding | 63.99M | 61.34M | 42.42M | 53.79M | 47.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
